

Anti-CDK9 (pT186) Antibody
Rabbit polyclonal antibody to CDK9 (pT186)
Catalog # AP61077**Specification****Anti-CDK9 (pT186) Antibody - Product Information**

Application	WB
Primary Accession	P50750
Other Accession	Q99J95
Reactivity	Human, Mouse, Rat, Pig, Chicken, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	42778

Anti-CDK9 (pT186) Antibody - Additional Information**Gene ID** 1025**Other Names**

CDC2L4; TAK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit

Target/Specificity

Recognizes endogenous levels of CDK9 (pT186) protein.

Dilution

WB~~WB (1/500 - 1/1000)

Format

Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide.

Storage

Store at -20 °C. Stable for 12 months from date of receipt

Anti-CDK9 (pT186) Antibody - Protein Information

Name CDK9 {ECO:0000303|PubMed:10903437, ECO:0000312|HGNC:HGNC:1780}

Function

Protein kinase involved in the regulation of transcription (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:>14701750, PubMed:>16109376, PubMed:>16109377, PubMed:>20930849, PubMed:>28426094, PubMed:>29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed:>10574912, PubMed:>10757782, PubMed:>11145967, PubMed:>11575923, PubMed:>11809800, PubMed:>11884399, PubMed:>14701750, PubMed:>16109376, PubMed:>16109377, PubMed:>16427012, PubMed:>20930849, PubMed:>28426094, PubMed:>30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed:>10574912, PubMed:>10757782, PubMed:>11145967, PubMed:>11575923, PubMed:>11809800, PubMed:>11884399, PubMed:>14701750, PubMed:>16109376, PubMed:>16109377, PubMed:>20930849, PubMed:>28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed:>10912001, PubMed:>11112772, PubMed:>12037670, PubMed:>16427012, PubMed:>20081228, PubMed:>20980437, PubMed:>21127351, PubMed:>9857195). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed:>17956865, PubMed:>18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed:>10393184, PubMed:>11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed:>15564463, PubMed:>19575011, PubMed:>19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and

H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed:15564463, PubMed:19575011, PubMed:19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed:20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed:20493174). Promotes cardiac myocyte enlargement (PubMed:20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed:21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed:10912001, PubMed:11112772, PubMed:9857195). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed:12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed:29335245).

Cellular Location

Nucleus. Cytoplasm. Nucleus, PML body. Note=Accumulates on chromatin in response to replication stress Complexed with CCNT1 in nuclear speckles, but uncomplexed form in the cytoplasm. The translocation from nucleus to cytoplasm is XPO1/CRM1- dependent. Associates with PML body when acetylated

Tissue Location


Ubiquitous.

Anti-CDK9 (pT186) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CDK9 (pT186) Antibody - Images



Western blot analysis of CDK9 (pT186) expression in PC3 (A), mouse liver (B), rat liver (C) whole cell lysates.

Anti-CDK9 (pT186) Antibody - Background

KLH-conjugated synthetic peptide encompassing a sequence within the center region of human CDK9. The exact sequence is proprietary.